# Sharps Technology Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Sharps Technology Inc.). ## Overview Sharps Technology Inc. is a U.S.-based medical device company focused on syringe products and related drug-delivery systems. Its business includes the marketing and distribution of safety and disposable syringes, with operations tied to both domestic and international healthcare markets through its own product lines and distribution relationships. ## Products & services • Safety syringes and disposable syringes • Securgard syringe product line • Sologard syringe product line • Drug-delivery systems and related packaging • Distribution of third-party complementary medical products - **Syringe products** (70%) — Safety, disposable, and prefillable syringe products sold for clinical and pharmaceutical use. - **Medical device distribution** (20%) — Marketing and distribution of syringe inventory and related healthcare products to end customers and distributors. - **Drug-delivery systems** (5%) — Related delivery components and packaging used with injectable therapies and syringe platforms. - **Digital asset treasury activities** (5%) — Staking-related revenue from digital asset holdings and treasury operations. - Safety syringes and disposable syringes - Securgard syringe product line - Sologard syringe product line - Drug-delivery systems and related packaging - Distribution of third-party complementary medical products ## Customers Sharps sells into healthcare channels that use syringes and injection-related products, including hospitals, clinics, healthcare providers, and medical supply organizations. It also targets healthcare companies, distributors, and government buyers in domestic and foreign markets, where procurement is driven by product safety, supply reliability, and regulatory compliance. - **Hospitals and clinics** (primary) — Buy disposable and safety syringes for routine patient care and injection workflows. - **Healthcare distributors** (primary) — Purchase inventory for resale into healthcare channels and supply contracts. - **Healthcare providers** (secondary) — Use syringe products directly in clinical and specialty applications. - **Government buyers** (secondary) — Procure syringe products for public health and institutional supply needs. - **Medical supply organizations** (secondary) — Source syringe inventory and related products for distribution networks. - Hospitals and clinics buying syringes for routine clinical use - Healthcare providers needing safety-focused injection products - Medical supply organizations and distributors reselling inventory - Healthcare companies sourcing syringe supply agreements - U.S. and foreign government buyers for public health procurement ## Geography Sharps is headquartered in the United States and maintains a corporate office in Melville, New York. Its product marketing and distribution reach both domestic and international markets, and the company also has a manufacturing-related footprint in Hungary through Safegard Medical. - United States is the corporate base and primary commercial market - Melville, New York is the company office location - Hungary hosts the Safegard syringe manufacturing facility - Products are marketed to domestic and international customers - Foreign employees and consultants support remote operations ## Strategy Sharps is focused on commercializing its syringe platforms through manufacturing, inventory availability, and distribution relationships. It also intends to broaden its platform by representing third-party medical products that serve the same customer base, while maintaining regulatory and quality compliance across markets. - **Commercialize syringe inventory and product lines** (short-term) — The company’s core value depends on converting designed and manufactured syringe products into repeatable sales. - **Expand distribution platform** (medium-term) — Adding complementary third-party products can broaden the customer wallet share and reduce reliance on a narrow product set. - **Maintain manufacturing and supply capability** (short-term) — Healthcare customers require dependable product availability and commercial quantities after orders are placed. - **Build compliance and quality credibility** (long-term) — Medical device distribution depends on FDA and international regulatory standards. - Commercialize Securgard and Sologard syringe platforms - Use inventory and supply agreements to support near-term sales - Expand from manufacturing into distribution of complementary products - Serve hospitals, distributors, and government buyers - Maintain FDA and international regulatory compliance ## Risks Sharps faces execution risk in commercializing a narrow syringe portfolio and in maintaining reliable supply, quality, and regulatory compliance across markets. The company also has exposure to inventory, manufacturing, and distribution risks, while its newer digital asset treasury activities add market, custody, and valuation volatility outside the core medical device business. - **Commercialization and demand risk** [high] — The company depends on converting syringe products and supply agreements into sustained customer orders. - **Inventory and manufacturing risk** [high] — The business has built inventory and relies on commercial quantities being available quickly after orders are placed. - **Regulatory compliance risk** [high] — Medical device sales and distribution require compliance with FDA and international quality standards. - **Trade policy and tariff risk** [medium] — International sourcing and distribution can be affected by tariffs and trade restrictions. - **Digital asset treasury risk** [high] — SOL holdings and staking revenue introduce price volatility, custody, and counterparty/operational risk. - Commercial adoption risk for syringe products and supply agreements - Inventory obsolescence and excess manufacturing cost exposure - Regulatory and quality compliance risk in medical devices - Foreign trade policy and tariff exposure - Digital asset volatility, custody, and staking-related risks ## Accounting Sharps’ reporting is affected by revenue timing on initial product shipments, inventory valuation, and fair value measurements tied to warrants and digital assets. The company also has judgment-heavy areas around impairment, derivative accounting, and foreign currency effects, which can materially change reported results from period to period. - **Revenue recognition** — Affects reported sales timing and quarter-to-quarter comparability - **Inventory reserve and net realizable value** — Can reduce gross margin and increase expense recognition - **Fair value of warrants and derivatives** — Can create large non-cash gains or losses in earnings - **Long-lived asset impairment** — Can produce significant write-downs - **Digital asset accounting** — Affects balance sheet value and non-operating results - Revenue recognition on syringe product shipments and supply orders - Inventory reserve and net realizable value judgments - Fair value accounting for warrants and derivative liabilities - Impairment of long-lived assets and facility-related estimates - Digital asset valuation, staking revenue, and transaction fees --- *Last updated: 2026-04-29T04:58:20.884196+00:00*